Kate Chappell

Research Fellow - Biostatistics

Menzies Institute for Medical Research

  • Research Fellow - Biostatistics
    Menzies Institute for Medical Research

FUNDED PROJECTS

  • CONSULTANCY/CONTRACT RESEARCH
    Time to deterioration
    1 Oct 2024 - 1 Jan 2025
    People funded by this grant:
    • Roydhouse J,
    • Wills K,
    • Breslin M,
    • Otahal P,
    • Chappell K
    Project Total: $78,046; Time-to-deterioration (TTD) analyses have been used frequently for patient-reported outcome (PRO) endpoints in cancer trials, however both methodological and conceptual concerns have been raised about the use of TTD analyses. Specifically, there are concerns relating to 1) the definition of the PRO event, 2) the handling of competing risks such as death and progression. The proposed analyses aim to consider both issues and provide an evidence-based update to guide statisticians and triallists interested in using TTD for PRO data in cancer trials. The analyses will also be conducted using the estimand framework, which has been adopted or is in the process of adoption by regulatory agencies globally. This will position the analyses within ongoing developments. Funded by: Gilead Sciences ($78,046); University of Tasmania.